The GENEFLAMMATION Framework
The universal human disease. The shared biological substrate from which the full spectrum of chronic illness emerges, identified and named by Alberto Rivera, MD, FAAPMR.
The Oxygen Free Radical Crisis is not a diagnosis. It is a polygenic state, a convergence of genetic vulnerabilities across antioxidant, methylation, detoxification, and inflammatory regulatory pathways that results in sustained oxidative injury across every tissue the body possesses.
When the enzymes that neutralize reactive oxygen species are genetically attenuated, when methylation efficiency is compromised by variant MTHFR and COMT alleles, when detoxification pathways cannot clear the metabolic burden of modern life, and when inflammatory regulatory genes are set to amplify rather than resolve — the result is a systemic environment in which disease is not an accident. It is an inevitability.
Dr. Rivera argues that this convergence — the Oxygen Free Radical Crisis — is the upstream driver of heart disease, diabetes, neurodegeneration, autoimmunity, chronic pain, and the full spectrum of conditions that medicine has historically treated as separate entities. They are not separate. They share a single biology, written in the genome, and readable by those with the tools to read it.
Variants in SOD2, CAT, GPX1, and NQO1 determine your innate capacity to neutralize reactive oxygen species. When these pathways are genetically compromised, oxidative burden accumulates unchecked, initiating the cascade that drives chronic disease.
MTHFR, COMT, MTR, and MTRR variants govern methylation efficiency — the biochemical process that regulates gene expression, neurotransmitter metabolism, and detoxification. Methylation failure is a force multiplier for every other inflammatory pathway.
GSTT1, GSTM1, CYP1B1, and related phase I and II detoxification enzymes determine how effectively your body neutralizes environmental toxins, metabolic byproducts, and xenobiotics. Impaired detoxification extends the half-life of every inflammatory stimulus.
IL-6, TNF-α, IL-1β, and NF-κB pathway variants set the gain on your inflammatory response. High-gain genotypes produce disproportionate inflammatory signaling in response to ordinary biological stressors, sustaining inflammation long after the trigger has passed.
The Clinical Response
GENEFLAMMATION is the precision genomics platform Dr. Rivera built to translate this polygenic architecture into individualized therapeutic strategy. By mapping a patient's specific variant profile across all four pathway clusters, GENEFLAMMATION produces a therapeutic roadmap that addresses root cause — not symptoms.
See The Inflammation Protocol